
Seoul International Digestive Disease Symposium 2025



April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea

Frontiers in Digestive Research and Practice

Name	Jae-Ho Cheong
Affiliation	Yonsei University College of Medicine
Country	KOREA
Major Field	

Educational Background

5	
1989-1995 Yonsei University, Seoul, KOREA	M.D.
2003-2006 Yonsei University, Seoul, KOREA	Ph.D.
2006-2009 UT MD Anderson Cancer Center, Houston, Tx	Postdoc

Professional Experience	
2007-2009	Odyssey Fellow, Department of Systems Biology, Kleberg Center for Molecular Markers,
	UT MD Anderson Cancer Center
2006-	Professor, Department of Surgery, Yonsei University College of Medicine, Seoul, KOREA
2017-	Vice Dean, Research Affairs, Yonsei University College of Medicine, Seoul, Korea
2019-	Director, Institute for Precision Cancer Therapy, Yonsei Cancer Center, Yonsei
	University College of Medicine

Main Scientific Publications

- 1. Bioprinted Organoids Platform with Tumor Vasculature for Implementing Precision Personalized Medicine Targeted Towards Gastric Cancer. J Kim, J Kim, G Gao, Y Choi, J Kim, DW Cho, JH Cheong, J Jang. Advanced Functional Materials (IF: 19) 2024; 34 (11), 2306676
- 2. PHGDH preserves one-carbon cycle to confer metabolic plasticity in chemoresistant gastric cancer during nutrient stress. PNAS (IF:12.779) 2023;120:e2217826120
- 3. ACTA2 expression predicts survival and is associated with response to immune checkpoint inhibitors in gastric cancer. Clinical Cancer Research (IF:13.801) 2023;29:1077-1085
- 4. Clinical molecular subtyping reveals intrinsic mesenchymal reprogramming in gastric cancer cells. Exp Mol Med 2023 (IF:12.172)
- 5. PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models. BMC medicine (IF:11.45) 2023; 21 (1), 1-175.
- 6. Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. Nature Commun (IF:17.694) 2022;13:774
- 7. Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer. Nature Biomedical Engineering (IF:25.67) 2021
- 8. <u>Cheong JH*</u>, Yang HK, Kim H, Kim WH, Kim YW, Kook MC, Park YK, Kim HH, Lee HS, Lee KH, Gu MJ, Kim HY, Lee J, Choi SH, Hong S, Kim JW, Choi YY, Hyung WJ, Jang E, Kim H, Huh YM, Noh SH. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol (IF:36.4) 2018 May;19(5):629-638
- 9. Lee J, Kim H, Lee JE, Shin S-J, Oh J, Kwon S, Kim H, Choi YY, White M, Paik S, <u>Cheong JH*</u> and Kim H*. Selective cytotoxicity of the NAMPT inhibitor FK855 toward gastric cancer cells with markers of the epithelial-mesenchymal transition, due to loss of NAPRT. Gastroenterology (IF:20.8)
- 10. Choi YY, Kim H, Shin SJ, Kim HY, Lee J, Yang HK, Kim WH, Kim YW, Kook MC, Park YK, Kim HH, Lee HS, Lee KH, Gu MJ, Choi SH, Hong S, Kim JW, Hyung WJ, Noh SH, <u>Cheong JH*</u>. Microsatellite instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg (IF:9.2). 2019 Aug;270(2):309-316

